Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data

ABSTRACT: The HIV pandemic has led to close to 40 million people living with HIV (PLWH) worldwide. To date, SARS-CoV2 has affected > 220 million people, and unprecedented global efforts have resulted in almost 6000 million doses of SARS-CoV2 vaccines being administered. Although several specific COVID-19 antiviral and anti-inflammatory treatments and SARS-CoV2 vaccines have been approved, the data available to support their use in specific populations such as PLWH remain limited. PLWH includes a range of individuals from practically unaffected immunity to severely immunocompromised individuals, and preventive and therapeutic interventions should be tailored for these subgroups . However, in most randomized clinical trials regarding antivirals, immunomodulators and vaccines for COVID-19, PLWH have been excluded or only enrolled in small numbers leading to a paucity of data. We briefly discuss the current evidence for prevention and treatment of COVID-19 in PLWH and identify key areas where more information is required.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40121-021-00547-y.

SUBMITTER: Diaz N 

PROVIDER: S-EPMC8552207 | biostudies-literature |

REPOSITORIES: biostudies-literature